Collectively we have
Created
$25B+
in Value
Raised
$5B+
of Capital
Orchestrated
180+
M&A Deals
Therapeutic Areas
15+
Therapeutic Areas
Worked Across
The SKIA Team
A strategy built on complex situations is only as good as the people executing it, and this is where SKIA is most grounded. Our partners have collectively generated more than $25 billion in value, raised over $5 billion in capital, completed more than 180 M&A transactions, and worked across more than 15 therapeutic areas. Each partner brings decades of investment, strategic, and operational experience. Importantly, they have all done this work before: the company-builds, the exits, the turnarounds, and the deals that this model depends on.
Jayson Dallas, MD MBA
CEO / Co-Founder
25 years of global biopharma leadership. Former CEO of Aimmune and Rivus; CCO at Ultragenyx. Previously a director at Arena, Galecto, Antag and Faeth.
Carl Goldfischer, MD
CIO / Co-Founder
Managing Director at Bay City Capital since 2000. Over 30 years of healthcare investment experience.
Amit Munshi
Exec Chair / Co-Founder
35 years in biotech operations. Led Arena ($6.7B acquisition by Pfizer), Longboard ($2.6B), and Kythera ($2.1B). Boards: Inhibikase, Zura, Sensorion.
Stephen Sands
Vice-Chair / Co-Founder
35 years of financial advice to life sciences. Former Vice Chairman at Goldman Sachs and Head of Healthcare Banking at Lazard. Advised on over 180 M&A transactions.
Chandler Glass
VP, Strategic Development
Co-founder of Aviator Biosciences, a clinical stage biotech company developing novel therapeutics for genetic cardiomyopathy and heart failure. Previously served in corporate development roles at multiple companies including Kyverna and Cellarity.
Ralph Lin, PhD
CBO
Over 20 years of experience delivering $20B+ in transaction value. Expert in biopharma M&A, platform licensing, and global healthcare alliances.
Doug Bakan, PhD
CTO
35+ years operational experience in CMC, Quality, and Regulatory activities for discovery, clinical, and commercial stage pharmaceutical products. Executive and technical expertise in small molecule, biologic, and cell therapy assets, most recently at Arena Pharmaceuticals, Ventyx Biosciences, and Kailera Therapeutics.
Laurie Stelzer
CFO
25 years of global biopharma leadership. Former CFO of Mirati, Arena, Halozyme, Kailera, and Renegade/Orna. Currently director of Spyre, Sionna, MBX and PMV.
Joan Schmidt
GC
30 years of international leadership in the life sciences industry. Former Chief Legal Officer and Board Secretary at Arena Pharmaceuticals, Inc., Pharvaris NV and DBV Technologies SA. Â Previously, Global Deputy General Counsel at Novo Nordisk A/S.
Our Advisors
Fred Craves, PhD
Founder of Bay City Capital. 35+ years of investment and company formation experience. Director of Madrigal and several private companies. Trustee of the Gladstone Institute.Â
Amy Wechsler, MD MBA
Board certified Dermatologist and Psychiatrist in private practice. Advisor to Chanel Skin Care for 14 years. Board member of Bausch Health, Galecto. ​​
Steve Tulk
35+ years of technology leadership across life sciences and global brands. Currently CTO of Vaniam Group. Previously CTO of closerlook (acquired by Fishawack Health), BMG360, and Kaptivating Technology; executive roles at Nike, Vivendi, and Pharmacia & Upjohn. Multiple AI and data patents. Board member Advisys.